Reduced-Nicotine Cigarettes May Reduce Smoking in Anxious, Depressed Smokers

Reduced-Nicotine Cigarettes May Reduce Smoking in Anxious, Depressed Smokers

Lonely Smoking

According to a new study by Harvard and Penn State researchers, lowering the amount of nicotine in cigarettes may reduce smoking without worsening mental health in smokers with mood or anxiety disorders.

Decreasing the amount of nicotine in cigarettes to non-addictive levels may reduce smoking without worsening mental health in smokers with mood or anxiety disorders. This is according to new research from scientists at Penn State College of Medicine and Harvard Medical School. They said that lowering the nicotine content in cigarettes could also lessen addiction, lower exposure to toxic substances, and improve a smoker’s chances of quitting.

According to the CDC, cigarette smoking remains the leading cause of preventable disease, disability, and death in the United States. It accounts for more than 480,000 deaths every year, or about 1 in 5 deaths.

Tobacco remains the leading preventable cause of premature death and disease in the United States. Recent proposals by the U.S. Food and Drug Administration (FDA) and the New Zealand government seek to limit the amount of nicotine in cigarettes to minimally addictive levels. Although previous research suggests that reducing nicotine content could help smokers quit, there is little evidence to demonstrate if these policies could adversely affect smokers with current or prior affective disorders such as depression and anxiety disorders. This is critical, as these conditions affect an estimated 38% of U.S. cigarette smokers.

According to Jonathan Foulds, professor of public health sciences and of psychiatry and behavioral health, smokers with mental health conditions are more likely to have severe nicotine withdrawal symptoms and less success at quitting. He also said there is speculation that lessening nicotine content to very low levels could worsen psychiatric symptoms in smokers with mental health conditions and lead to heavier smoking and increased exposure to toxicants, or harmful chemicals.

The researchers studied 188 smokers with a history of or who had a current mood or anxiety disorder and had no plans to quit. Volunteer participants were randomly assigned to a group that received either research cigarettes containing the usual amount of nicotine (11.6 mg nicotine/cigarette) or a progressively reduced amount of nicotine for an additional 18-week period (the final amount was 0.2 mg nicotine/cigarette). At the beginning and conclusion of the study, the researchers measured levels of cotinine, a metabolite of nicotine, levels of harmful chemicals, cigarette dependence indexes and various mental health measures.

In 2020, 12.5% of U.S. adults currently smoked cigarettes, meaning an estimated 30.8 million adults in the United States currently smoke cigarettes. More than 16 million Americans live with a smoking-related disease.

The researchers observed no statistically significant differences in mental health measures between the two groups at the conclusion of the study. The team used the Kessler Psychological Distress Scale, a six-item self-report assessment where participants reported on a 5-point scale the degree to which they experienced feelings or emotions like “nervous,” “hopeless” or “so depressed that nothing could cheer them up.” Scores are developed by summing points for the six experiences. Participants in the reduced nicotine content group scored an average of 5.3 at the beginning of the study and finished at an average score of 4.6, while participants in the usual nicotine content group scored 6.1 at the beginning of the study and finished around 4.9.

“These findings are important because we want to understand the effect these policies would have on smokers with anxiety or depressive disorders,” said Foulds, a Penn State Cancer Institute researcher. “Our data showed that there wasn’t a significant difference in mental health measures between the groups, suggesting reduced nicotine cigarettes might not have adverse psychological effects on this population.”

Similar to what prior studies reported, Foulds and team found that groups in the reduced nicotine content group were absorbing lower amounts of nicotine and ingesting lower levels of harmful carcinogens such as the biomarker 4-(methylnitrosamino)-1-(3-pryidyl)-1-butanol), more commonly known as NNAL. That group also smoked fewer cigarettes and reported lower levels of nicotine addiction by the end of the randomized phase of the trial. The results were published in PLOS ONE today, Nov. 2.

Unique to this study, participants in both groups were also given the choice to “choose their treatment,” after the 18-week period. They could go back to using their own cigarettes, continue smoking the research cigarettes or attempt to quit. Of the 188 participants in the study, those randomized to reduced nicotine content cigarettes were more likely to have quit smoking 12 weeks later (18.1%), compared to those in the control (usual nicotine content) group (4.3%).

“We believe this is the first randomized trial to find that smokers who used very low nicotine cigarettes were significantly more likely to have quit smoking (with biochemical verification), three months after the end of the trial,” Foulds said.

“Our results suggest that these policies will likely result in reduced nicotine absorption from cigarettes without worsening the mental health of smokers with mood or anxiety disorders,” said Dr. Eden Evins, Cox Family Professor of Psychiatry at Harvard Medical School. “They also suggest that with proper support and resources, smokers with mood and anxiety disorders could quit successfully as a result of these policies.”

Reference: “The effects of reduced nicotine content cigarettes on biomarkers of nicotine and toxicant exposure, smoking behavior and psychiatric symptoms in smokers with mood or anxiety disorders: A double-blind randomized trial” by Jonathan Foulds, Susan Veldheer, Gladys Pachas, Shari Hrabovsky, Ahmad Hameed, Sophia I. Allen, Corinne Cather, Nour Azzouz, Jessica Yingst, Erin Hammett, Jennifer Modesto, Nicolle M. Krebs, Courtney Lester, Neil Trushin, Lisa Reinhart, Emily Wasserman, Junjia Zhu, Jason Liao, Joshua E. Muscat, John P. Richie Jr. and A. Eden Evins, 2 November 2022, PLOS ONE.
DOI: 10.1371/journal.pone.0275522

For more information on nicotine, smoking, and health studies at the Penn State Center for Research on Tobacco and Health, visit https://research.med.psu.edu/smoking/#participants.

Susan Veldheer, Ahmad Hameed, Sophia Allen, Jessica Yingst, Erin Hammett, Jennifer Modesto, Nicolle Krebs, Courtney Lester, Neil Trushin, Lisa Reinhart, Emily Wasserman, Junija Zhu, Jason Liao, Joshua Muscat and John Richie of Penn State College of Medicine; Shari Hrabovsky of Penn State Ross and Carol Nese College of Nursing; and Gladys Pachas, Corinne Cather, Nour Azzouz and A. Edin Evins of Harvard Medical School also contributed to this research. Foulds and Evins have done paid consulting for pharmaceutical companies involved in producing smoking cessation medications. Other author conflicts of interest are noted in the manuscript.

This research was supported by the National Institutes of Health through the National Institute on Drug Abuse of the National Institutes of Health (award P50DA036107) and the National Center for Advancing Translational Sciences through Penn State Clinical and Translational Science Institute (award UL1 TR000127). The research was also supported by the Center for Tobacco Products of the U.S. Food and Drug Administration. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Food and Drug Administration.

CBD Oil, 9 Most Well Guarded Secrets About Cannabinoid
Find out more